In summary, this study provides first evidence to support that human SND1 oncogene is under the control of SREBP-2 and SREBP-1 and points to a novel SREBPs/SND1 pathway that highlights the necessity for defining their upstream modulating signals and their downstream effector molecules to better understand the relative contribution of SND1 to lipid metabolism in liver cancer cells. The gene discussed is SND1; the disease is liver cancer.